CEO of Publicly Traded Firm Falsifies and Fabricates Bank Records in $212,000,000 Investment Fraud Scheme: DOJ
The former CEO of a publicly traded healthcare services company has been sentenced to five years in prison for his role in a $212.5 million investment fraud scheme.
The U.S. Department of Justice (DOJ) says Parmjit Parmar, also known as Paul Parmar, pleaded guilty to conspiracy to commit securities fraud and was sentenced on May 5, 2026.
Prosecutors say Parmar, 55, of Colts Neck, New Jersey, was also sentenced to three years of supervised release and ordered to pay more than $125 million in victim restitution.
The DOJ says Parmar and his co-conspirators orchestrated a scheme from May 2015 through September 2017 to defraud a private investment firm and others in connection with a transaction to take private a healthcare services company traded on the London Stock Exchange’s Alternative Investment Market.
To fund the transaction, a private investment firm contributed about $82.5 million, while a consortium of financial institutions contributed another $130 million.
Prosecutors say the conspirators used fraudulent methods to inflate the value of the company, including phony customers, altered bank statements and fabricated bank records tied to subsidiary entities.
The DOJ says the conspirators also funneled proceeds from secondary offerings through bank accounts they controlled and used the money for purposes unrelated to acquiring the purported targets.
The scam was uncovered in September 2017, when Parmar and his co-conspirators resigned or were terminated. The company and affiliated entities filed for bankruptcy on March 16, 2018, attributing the financial collapse in large part to the fraud scheme.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nebius Q3 results exceed expectations, capital expenditure rises to $27 billion, ARR target postponed, stock falls over 14% pre-market | Earnings Report Insights
Nebius reported Q3 revenue of $981 million (a year-on-year increase of 571%) and adjusted EBITDA of $466 million, both exceeding expectations. However, the company delayed and lowered its guidance for annual recurring revenue (ARR), stating that it is no longer applicable. Additionally, it significantly raised its 2026 capital expenditure target to $27 billion, with projections to further increase to $40 billion to $45 billion in 2027. The stock price plummeted more than 14% in pre-market trading.
